Welcome to our dedicated page for VIEMED HEALTHCARE SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
VIEMED HEALTHCARE, INC. (VMD) released an August 2026 investor presentation describing a rapidly growing, home-based clinical care platform in complex respiratory and related services, plus updated financial performance and 2026 guidance.
For 2025, net revenue was $270 million, up 21% year over year, with Adjusted EBITDA of $61.4 million (22.7% margin), free cash flow of $28.1 million, and net income attributable to VMD of $14.9 million. The company reports serving over 198,000 patients across all 50 states, with ventilation remaining the largest line but an expanded mix including sleep, oxygen, airway clearance, women’s health and staffing.
For 2Q 2026, revenue was $78.1 million (up 24% year over year), Adjusted EBITDA $13.7 million, and free cash flow $8.6 million, with no net debt and $10.7 million of cash plus $46 million of undrawn credit facilities. Management’s 2026 guidance calls for net revenue of $314–$320 million and Adjusted EBITDA of $64–$68 million, with net capex of 8.5%–10% of net revenue and continued share repurchases under a program authorizing up to 5% of shares outstanding.
VIEMED HEALTHCARE, INC. (VMD) reported equity compensation and an RSU conversion by director Kaushal Nitin. On August 19, 2026, 18,786 Restricted Stock Units were exercised/converted into 18,786 common shares, bringing his directly held common shares to 161,361. Each RSU represents a contingent right to receive one common share. Separately, on August 17, 2026, he received a grant of 15,217 RSUs tied to an equal number of common shares, scheduled to vest on August 17, 2027.
VIEMED HEALTHCARE, INC. (VMD) director Sabrina Heltz reported several equity-compensation transactions. On August 19, 2026, 15,029 Restricted Stock Units and 3,757 Phantom Share Units vested and were converted into common shares, with the phantom-share-related common shares simultaneously returned to the company for cash at $8.94 per share. On August 17, 2026, she received new awards of 12,174 RSUs and 3,043 Phantom Share Units, each representing one common share or its cash value and scheduled to vest on the first anniversary of the grant date, with the RSUs expiring on August 17, 2027.
VIEMED HEALTHCARE, INC. (VMD) director Randy E. Dobbs reported a series of equity award events. On August 19, 2026, previously granted 16,763 Restricted Stock Units and 4,191 Phantom Share Units vested and were settled, resulting in the acquisition of corresponding common shares and a simultaneous disposition of 4,191 common shares to the company for cash at $8.94 per share. The phantom units are cash-settled awards economically equivalent to common shares. On August 17, 2026, Dobbs also received a new grant of 16,848 Restricted Stock Units that vest on the first anniversary of the grant date.
For VIEMED HEALTHCARE, INC. (VMD), director Timothy Smokoff reported several equity compensation events. On August 19, 2026, previously granted Restricted Stock Units and Phantom Share Units vested and were exercised or settled into a total of common shares, with 3,757 common shares then returned to the company in a disposition at $8.94 per share. Separately, on August 17, 2026, he received new grants of 12,174 Restricted Stock Units and 3,043 Phantom Share Units, each convertible into an equal number of common shares and scheduled to vest on the first anniversary of the grant date. These transactions were not reported as made under a Rule 10b5-1 trading plan.
Viemed Healthcare, Inc. reported Q2 2026 revenue of 78,097 thousand USD, up 23.9% from 63,056 thousand a year earlier, driven by growth in ventilator rentals, other home medical equipment, and equipment and supply sales, including contributions from the Lehan Drugs acquisition.
Gross profit rose to 45,048 thousand USD, but income from operations slipped to 4,461 thousand and net income attributable to Viemed decreased to 2,764 thousand, with diluted EPS of 0.07 versus 0.08. Adjusted EBITDA was 13,715 thousand, as higher selling, general and administrative costs and losses on asset disposals weighed on margins.
For the first six months of 2026, net cash provided by operating activities increased to 23,973 thousand USD, funding 15,172 thousand of capital expenditures and continued debt reduction. Debt under the 2022 Senior Credit Facilities declined to 7,445 thousand, cash ended at 10,680 thousand, and total assets reached 204,224 thousand.
Viemed Healthcare reported record second-quarter 2026 net revenue of $78.1 million, up 23.9% from a year earlier and 3.6% sequentially. Net income attributable to the company was $2.8 million, or $0.07 per diluted share, while Adjusted EBITDA was $13.7 million, a 4.0% year-over-year decrease. The company generated $15.9 million of operating cash flow and $8.6 million of free cash flow in the quarter.
Viemed ended June 30, 2026 with $10.7 million in cash, long-term debt of $6.4 million, working capital of $6.1 million, and $46 million available under existing credit facilities. The company reported a record 12,635 ventilator patients, plus strong growth in PAP therapy and sleep resupply patients, and repurchased 530,802 shares for $5.1 million. Full-year 2026 net revenue guidance was raised to $314–$320 million, Adjusted EBITDA guidance set at $64–$68 million, and net capital expenditures are now expected at 8.5%–10.0% of net revenue.
Viemed Healthcare, Inc. is the subject of an amended Schedule 13G filing by Forager Fund, L.P., Forager Capital Management, LLC, and individuals Edward Kissel and Robert MacArthur. The reporting group states that, in the aggregate, they beneficially own 1,886,872 shares of Viemed common stock.
This position represents 4.9% of the 38,336,802 shares of common stock outstanding as of April 29, 2026, as reported in Viemed’s Form 10-Q for the quarter ended March 31, 2026. Forager Fund and its general partner each have sole voting and dispositive power over these shares, while Messrs. Kissel and MacArthur report shared voting and dispositive power over the same 1,886,872 shares, reflecting their roles in managing the fund. The filing notes that the group’s holdings are at or below the 5 percent ownership threshold.
Viemed Healthcare Chief Medical Officer William Frazier reported an exercise-and-sell transaction in Viemed Healthcare, Inc. common shares. He exercised stock options for 10,000 Common Shares at $1.81 per share, then sold 10,000 Common Shares in an open-market sale at $11.72 per share on the same date.
After these transactions, Frazier directly holds 73,214 Common Shares and retains 26,261 Stock Options, which are fully vested and expire on January 4, 2028. The filing shows a net reduction of 10,000 common shares in his direct holdings.
VIEMED HEALTHCARE, INC. director Timothy Smokoff reported open-market sales of a total of 20,000 Common Shares of VMD on June 24, 2026. The transactions were executed in five separate trades at prices ranging from $11.41 to $11.56 per share.